Setback prompts rethink of latency-reversing strategy to eliminate HIV infection

Antiretroviral drugs have been spectacularly effective in controlling HIV by hobbling the virus’s ability to infect cells, but they do not deplete the reservoirs of latently infected cells that remain a major barrier to a cure. One appealing solution to this problem has been latency-reversing agents (LRAs) that can reactivate the dormant virus, bringing it out of hiding so that it can be targeted and killed. The first-generation LRAs, however, have recently hit a snag. Four frontrunners that had shown potential in cell-culture models and preliminary clinical studies are
only minimally effective in a patient cell assay, shows a new study. A fifth compound, although more potent, is likely to be too toxic for
clinical use.

[Read more at Nature Reviews Drug Discovery (paywall) or download PDF // May 30, 2014]